Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YY001 in Moderate to Severe Glabellar Lines
NCT06583486Phase 3Completed
- Sponsor
- Claruvis Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in glabellar lines, sponsored by Claruvis Pharmaceutical. Started Mar 2024; status: completed.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06583486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06583486.